Form 4 for INMB Inmune Bio, Inc.
Accepted 2022-03-23 00:00:00 ET · period of report 2022-03-21 · accession 0001213900-22-014499 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-23 | 2022-03-22 | INMB | Ganjei James Kelly | Dir | A - Grant | $8.43 | +17.8K | 17.8K | New | +$150.0K |
| D | 2022-03-23 | 2022-03-21 | INMB | Ganjei James Kelly | Dir | A - Grant | $0.00 | +35.0K | 35.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-22 | A | A | 17,793 | $8.43 | 17,793 | D | — | — | (F1) The purchase price of the common stock being reported is the closing price per share immediately preceding the entering into of the binding agreement to issue the securities. These shares were purchased by the Reporting Person directly from Issuer. |
| 2 | Derivative | Option (right to buy) | 2022-03-21 | A | A | 35,000 | $0.00 | 35,000 | D | $7.92 · — to 2032-03-20 | 35,000 Common Stock | (F2) Granted pursuant to the 2021 Stock Incentive Plan. One third (1/3) of the Option will vest at the one-year anniversary of the grant date and the remaining unvested Option will become vested and exercisable 1/24th every month thereafter until the Option is 100% vested which shall occur on the three-year anniversary of the grant date. |